Eton Pharmaceuticals
Market cap $1.84B 28.8M shares (10-Q, Nov 2, 2026) × $63.65 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- INCRELEX trial start2H 2026INCRELEX trial start, 2H 2026, routine
- Amglidia NDA filingnear the end of 2026 or early 2027Amglidia NDA filing, near the end of 2026 or early 2027, notable
- ZENEO hydrocortisone autoinjector NDA filing2027ZENEO hydrocortisone autoinjector NDA filing, 2027, notable
- ET-700 extended-release zinc NDA filing2027ET-700 extended-release zinc NDA filing, 2027, notable
- ASN-001 NDA filingJan 2027ASN-001 NDA filing, Jan 2027, notable
- VALTOCO / LIBERVANT 12+ FDAJan 10, 2027VALTOCO / LIBERVANT 12+ FDA, Jan 10, 2027, material
- LIBERVANT PDUFA dateMar 29, 2027LIBERVANT PDUFA date, Mar 29, 2027, thesis-defining
- KHINDIVI FDA approvalMay 28, 2027KHINDIVI FDA approval, May 28, 2027, major
- ET-700 extended-release zinc trial start~2028ET-700 extended-release zinc trial start, ~2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (17 active programs)
ALKINDI SPRINKLE
KHINDIVI · hydrocortisoneGALZIN
zinc acetatePKU GOLIKE
carglumic acid
betaine anhydrous
nitisinone
DESMODA
desmopressin acetate · ET-600Amglidia
glyburidehydrocortisone
ET-800- Undisclosed indication
ZENEO
hydrocortisonezinc acetate
ET-700timolol topical gel
ASN-001- Infantile Hemangioma
IMPAVIDO
miltefosineLIBERVANT
diazepamINCRELEX
mecasermin · ET-900HEMANGEOL
propranolol- Infantile Hemangioma
Capital (as filed)
- Cash
- $55.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- $35.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $55.6M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (13)
- 2026-11-06 UPDATE: Eton Pharmaceuticals (ETON) - The Record Quarter and the First Real Miss ★ Distilled Pro
- 2026-10-15 UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Walks Into Neurology ★ Distilled Pro
- 2026-08-20 UPDATE: Eton Pharmaceuticals (ETON) - The Stock Goes Vertical, and the CEO Files to Sell 🔒 Paid
- 2026-08-14 UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Raises Guidance Twice in Three Months 🔒 Paid
- 2026-08-06 UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Buys the Other Half of the Hemangioma Market 🔒 Paid
- 2026-07-30 UPDATE: Eton Pharmaceuticals (ETON) - The July Catalyst Lands, and It Lands Clean 🔒 Paid
- 2026-05-19 UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Bolts On Asset #11 🔒 Paid
- 2026-05-15 UPDATE: Eton Pharmaceuticals (ETON) - Guidance Goes Up, Stock Goes Up, Thesis Goes Up 🔒 Paid
- 2026-04-28 UPDATE: Eton Pharmaceuticals (ETON) - The Wilson Disease Shot Clock Starts 🔒 Paid
- 2026-03-21 UPDATE: Eton Pharmaceuticals (ETON) - Delivers the Receipts, Margins Rebound, and the Market Finally Pays Up. 🔒 Paid
- 2026-03-08 UPDATE: Eton Pharmaceuticals (ETON) - Bags Its 10th Commercial Asset (HEMANGEOL)... 🔒 Paid
- 2026-03-01 UPDATE: Eton Pharmaceuticals (ETON) Executes on Cue 🔒 Paid
- 2026-02-19 Eton Pharmaceuticals (ETON): Scientific Deep Dive for ALKINDI SPRINKLE and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (13 calls)
Every verdict Biotech Distilled has published on Eton Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-19 Buy core Eton Pharmaceuticals (ETON): Scientific Deep Dive for ALKINDI SPRINKLE and Pipeline Products Eton is a de-risked, cash-flowing commercial execution play in niche orphan markets with 19 consecutive quarters of sequential revenue growth and imminent de-risked catalysts via the 505(b)(2) pathway.
- 2026-03-01 Buy core UPDATE: Eton Pharmaceuticals (ETON) Executes on Cue DESMODA approved on its PDUFA date validates the 505(b)(2) strategy and adds a $30M–$50M high-margin asset; the sell-the-news flush makes the stock more attractive with regulatory risk removed.
- 2026-03-08 Buy core UPDATE: Eton Pharmaceuticals (ETON) - Bags Its 10th Commercial Asset (HEMANGEOL)... HEMANGEOL acquisition at ~1.2x sales multiple with zero external financing adds $11.7M annual revenue and demonstrates excellent operational leverage on an existing sales force.
- 2026-03-21 Buy core UPDATE: Eton Pharmaceuticals (ETON) - Delivers the Receipts, Margins Rebound, and the Market Finally Pays Up. Q4 margins rebounded to ~70% as guided, validating the one-time compression thesis, and the GARP rotation confirms the market is pricing Eton as a profitable growing specialty pharma.
- 2026-04-28 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The Wilson Disease Shot Clock Starts ET-700 pilot first patient dosed with management anchoring >$100M peak sales, converting Wilson disease from a 'someday' asset into a dated H2 2026 catalyst on top of an already cash-flowing base business.
- 2026-05-15 Buy core UPDATE: Eton Pharmaceuticals (ETON) - Guidance Goes Up, Stock Goes Up, Thesis Goes Up Q1 product sales +73% YoY, full-year guidance raised to >$120M, INCRELEX label harmonization cleared by FDA, and EBITDA margin floor set at >30%, confirming the compounder thesis.
- 2026-05-19 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Bolts On Asset #11 IMPAVIDO licensed for effectively zero upfront cash adds another capital-efficient revenue line on a fixed SG&A base, reinforcing the bolt-on cadence thesis.
- 2026-07-30 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The July Catalyst Lands, and It Lands Clean KHINDIVI bioequivalence to ALKINDI SPRINKLE achieved and PAS filed ahead of schedule, unlocking the under-5 pediatric AI population; execution record remains unbroken though valuation at ~11x forward revenue now embeds the pipeline.
- 2026-08-06 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Buys the Other Half of the Hemangioma Market ASN-001 topical timolol licensed for $3M upfront with completed Phase II/III showing 56% vs 15% placebo response and patent life to 2044, giving Eton both systemic and topical ends of the infantile hemangioma market.
- 2026-08-14 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Raises Guidance Twice in Three Months Q2 product sales +99% YoY, guidance raised to >$145M with >35% EBITDA margin floor absorbing ASN-001 spend, pulling the multiple down to ~8x and making the setup closer to fair value than the pipeline-priced 11x of July.
- 2026-08-20 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The Stock Goes Vertical, and the CEO Files to Sell CEO Form 144 on nine-year-old founder shares does not alter the business thesis of 99% growth at 43% EBITDA margin, but the 46.8% five-day run has re-expanded the multiple to ~11.8x forward revenue, reopening the valuation debate.
- 2026-10-15 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The Boring Machine Walks Into Neurology LIBERVANT diazepam buccal film licensed for $10M upfront with tentative FDA approval and dated regulatory path to April 2027 launch, though it requires a new neurology sales team and enters a competitive market, testing the operating-leverage thesis.
- 2026-11-06 Buy core UPDATE: Eton Pharmaceuticals (ETON) - The Record Quarter and the First Real Miss Record Q3 with 158% revenue growth and guidance raised to >$175M at ~7.8x forward revenue justifies maintaining BUY despite ET-700 pilot missing on copper blocking vs GALZIN (12% vs 46%), which resets the >$100M Wilson disease thesis to a reformulation lottery ticket.
- Long call · opened Feb 19, 2026 at $18.22 · +249.3% vs XBI +14.6% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (8 quotes from 5 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Company is on track to submit an NDA near the end of 2026 or early 2027, allowing for potential approval and launch in 2027.”
matched to Amglidia (glyburide oral suspension) · regulatory submission -
“KHINDIVI label expansion Prior Approval Supplement (PAS) accepted for review and assigned May 28, 2027 PDUFA date.”
matched to KHINDIVI (under-5 label expansion) · regulatory decision -
“Eton anticipates launching the product in April 2027.”
matched to LIBERVANT (ages 6 to 11) · regulatory decision
-
-
-
“The product is expected to become eligible for full approval in patients 12 years of age and above following the scheduled expiration of VALTOCO®’s orphan drug exclusivity on January 10, 2027.”
matched to LIBERVANT · regulatory decision -
“The NDA has a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2027.”
matched to LIBERVANT (ages 6 to 11) · regulatory decision
-
-
-
“The Company currently has eleven commercial rare disease products: INCRELEX®, HEMANGEOL®, ALKINDI SPRINKLE®, KHINDIVI™, DESMODA™, GALZIN®, PKU GOLIKE®, IMPAVIDO®, Carglumic Acid, Betaine Anhydrous and Nitisinone, with IMPAVIDO® scheduled for commercialization in September 2026.”
matched to KHINDIVI (under-5 label expansion) · regulatory decision
-
-
-
“Eton will run a bioavailability bridging study for ASN-001 and intends to submit the New Drug Application (NDA) upon completion of the study in the second half of 2027.”
matched to ASN-001 · regulatory submission
-
-
-
“Eton will run a bioavailability bridging study for ASN-001 and intends to submit the New Drug Application (NDA) upon completion of the study in the second half of 2027.”
matched to ASN-001 · NDA submission following bioavailability bridging study
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (39)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 5, 2026ReleaseEton Pharmaceuticals Reports Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseEton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateEton printed a blowout Q3 — $57.9M revenue, 49% Adjusted EBITDA margin, guidance raised to >$175M — but the ET-700 pilot data delivered a split verdict: excellent tolerability (1/12 AEs vs. 8/12 for GALZIN), underwhelming copper blockade (12% reduction vs. 46%), pushing the program back into reformulation and delaying the >$100M peak-sales catalyst into 2027 or beyond.
- Nov 5, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-700→ BD updateSummary on the 8-K
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseEton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
- Nov 2, 2026ReleaseEton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
- Nov 2, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO INFANTILE SPASMS
- Oct 29, 2026ReleaseEton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- Oct 14, 2026ReleaseEton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film→ BD updateSummary on the 8-K
- Oct 14, 20268-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO LIBERVANT LICENSING AGREEEMENT→ BD updateEton paid $10M upfront to license LIBERVANT (diazepam buccal film) for the U.S. seizure rescue market — a $450M+ opportunity that pushes the boring machine into neurology for the first time, with an April 2027 launch target contingent on final FDA approval.
- Sep 28, 2026ReleaseEton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
- Sep 28, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE IMPAVIDO LAUNCH
- Aug 27, 2026ReleaseEton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
- Aug 13, 2026ReleaseEton Pharmaceuticals Reports Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → ETON pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → ETON pipeline
- Aug 13, 202610-QQuarterly report
- Aug 5, 2026ReleaseEton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001BD extracted 2 program updates from this document → ETON pipeline
- Aug 5, 20268-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ASN-001BD extracted 1 program update from this document → ETON pipeline
- Aug 4, 20268-KCurrent report: officer / director change
- Aug 3, 2026ReleaseEton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
- Jul 29, 2026ReleaseEton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
- Jul 29, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO KHINDIVI
- Jun 9, 20268-KCurrent report: shareholder vote
- May 19, 2026ReleaseEton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
- May 19, 20268-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO HEMANGEOL LICENSING AGREEEMENT
- May 14, 2026ReleaseEton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
- May 14, 2026ReleaseEton Pharmaceuticals Reports First Quarter 2026 Financial Results
- May 14, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- May 14, 202610-QQuarterly report
- May 12, 2026ReleaseEton Pharmaceuticals to Participate in Upcoming Investor Conferences
- May 1, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE HEMANGEOL LAUNCH
- Apr 27, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-700.
- Apr 24, 2026DEF 14AProxy statement
- Apr 16, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO CFO APPOINTMENT.
- Apr 15, 20268-KCurrent report: material agreement, debt / obligation
- Mar 19, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Mar 19, 202610-KAnnual report
- Mar 2, 20268-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO HEMANGEOL LICENSING AGREEEMENT
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 6, 2026SCHEDULE 13G/A13G amendment
- Jul 28, 2026SCHEDULE 13G/A13G amendment
- Mar 26, 2026SCHEDULE 13G/A13G amendment
- Mar 6, 2026S-8Employee plan registration